These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23874572)

  • 41. Spotlight on sertraline in the management of major depressive disorder in elderly patients.
    Muijsers RB; Plosker GL; Noble S
    CNS Drugs; 2002; 16(11):789-94. PubMed ID: 12383038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study.
    Michelson D; Adler LA; Amsterdam JD; Dunner DL; Nierenberg AA; Reimherr FW; Schatzberg AF; Kelsey DK; Williams DW
    J Clin Psychiatry; 2007 Apr; 68(4):582-7. PubMed ID: 17474814
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.
    Pettinati HM; Oslin DW; Kampman KM; Dundon WD; Xie H; Gallis TL; Dackis CA; O'Brien CP
    Am J Psychiatry; 2010 Jun; 167(6):668-75. PubMed ID: 20231324
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial.
    Rossini D; Magri L; Lucca A; Giordani S; Smeraldi E; Zanardi R
    J Clin Psychiatry; 2005 Dec; 66(12):1569-75. PubMed ID: 16401159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.
    Oliveto A; Poling J; Mancino MJ; Williams DK; Thostenson J; Pruzinsky R; Gonsai K; Sofuoglu M; Gonzalez G; Tripathi S; Kosten TR
    Addiction; 2012 Jan; 107(1):131-41. PubMed ID: 21707811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction.
    O'Connor CM; Glassman AH; Harrison DJ
    J Clin Psychiatry; 2005 Mar; 66(3):346-52. PubMed ID: 15766301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder.
    Allgulander C; Dahl AA; Austin C; Morris PL; Sogaard JA; Fayyad R; Kutcher SP; Clary CM
    Am J Psychiatry; 2004 Sep; 161(9):1642-9. PubMed ID: 15337655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gender differences in treatment response to sertraline versus imipramine in chronic depression.
    Kornstein SG; Schatzberg AF; Thase ME; Yonkers KA; McCullough JP; Keitner GI; Gelenberg AJ; Davis SM; Harrison WM; Keller MB
    Am J Psychiatry; 2000 Sep; 157(9):1445-52. PubMed ID: 10964861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial.
    Mowla A; Kardeh E
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):970-3. PubMed ID: 21291943
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
    Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
    J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy.
    Aberg-Wistedt A; Agren H; Ekselius L; Bengtsson F; Akerblad AC
    J Clin Psychopharmacol; 2000 Dec; 20(6):645-52. PubMed ID: 11106136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Placebo-controlled trial of sertraline in the treatment of binge eating disorder.
    McElroy SL; Casuto LS; Nelson EB; Lake KA; Soutullo CA; Keck PE; Hudson JI
    Am J Psychiatry; 2000 Jun; 157(6):1004-6. PubMed ID: 10831483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improvements in irritability with sertraline versus placebo: Findings from the EMBARC study.
    Jha MK; Minhajuddin A; Chin Fatt C; Trivedi MH
    J Affect Disord; 2020 Oct; 275():44-47. PubMed ID: 32658822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L
    J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study.
    Dunner DL; Amsterdam JD; Shelton RC; Loebel A; Romano SJ
    J Clin Psychiatry; 2007 Jul; 68(7):1071-7. PubMed ID: 17685744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study.
    Van Ameringen MA; Lane RM; Walker JR; Bowen RC; Chokka PR; Goldner EM; Johnston DG; Lavallee YJ; Nandy S; Pecknold JC; Hadrava V; Swinson RP
    Am J Psychiatry; 2001 Feb; 158(2):275-81. PubMed ID: 11156811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective serotonin reuptake inhibitor treatment of major depressive disorder in children and adolescents.
    Newcorn JH
    Curr Psychiatry Rep; 2004 Apr; 6(2):85-7. PubMed ID: 15038909
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.